Hyperleptinemia May Protect From Cardio-Vascular Complications: A Small Georgian Study

Authors

  • Tamar Zerekidze Tbilisi State University, Department of Endocrinology, Tbilisi 0140
  • Shota Janjgava National Institute of Endocrinology, Metabolic Disorders, Tbilisi 0159
  • Ketevan Asatiani National Institute of Endocrinology, Metabolic Disorders, Tbilisi 0159
  • Elene Giorgadze National Institute of Endocrinology, Metabolic Disorders, Tbilisi 0159

DOI:

https://doi.org/10.3889/oamjms.2014.106

Keywords:

Leptin, Anthropometric parameters, Body composition, Cardio-vascular risk factors, Lipid panel

Abstract

BACKGROUND AND AIM: Leptin was assessed to play a coordinating role in obesity and its cardio-vascular complications, however the findings are conflicting and further clinical investigation is required. The aim of the present study was to evaluate the association of serum leptin with cardio-vascular risk factors in different body mass index and age groups.

MATERIALS AND METHODS:  One hundred and forty nine female patients were enrolled in the study and divided into groups according to body mass index (BMI) and age. Following measurements were carried out: height, weight, BMI, waist circumference, blood pressure. Venous blood sample was obtained for plasma leptin, insulin, glucose and lipid profile analysis. Insulin resistance index was calculated for each patient. Body fat distribution was measured using Dual energy X-ray Absorbtiometry.

RESULTS: The lowest leptin concentration was observed in overweight patients, the highest concentration was seen in obese patients. The difference between leptin levels were not observed in age groups. Leptin positively correlated with high density lipoprotein cholesterol levels in obese and elder patients.

CONCLUSION: Leptin might act as a preventive measure for cardiovascular complications only in the presence of sufficient amount of fat mass. Further studies are warranted in order to support these results.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

References

Shah NR, Braverman ER. Measuring Adiposity in Patients: The Utility of Body Mass Index (BMI), Percent Body Fat, and Leptin. PLoS One. 2012; 7: e33308.

Ren J. Leptin and hyperleptinemia - from friend to foe for cardiovascular function. J Endocrinol. 2004;181(1):1-10.

Caro JF, Sinha MK, Kolaczynski JW, Zhang PL, Considine RV. Leptin: the tale of an obesity gene. Diabetes. 1996; 45: 1455-1462.

Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, Ohannesian JP, Marco CC, McKee LJ, Bauer TL, and Caro JC. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med. 1999; 334: 292-295.

Oral EA, Simha V, Ruiz E, Andewelt A, Premkumar A, Snell P, Wagner AJ, DePaoli AM, Reitman ML, Taylor SI, Gorden P, Garg A. Leptin-replacement therapy for lipodistrophy. N Engl J Med. 2002; 346: 570-578.

Farooqi IS, Matarese G, Lord GM, Keogh JM, Lawrence E, Agwu C, Sanna V, Jebb SA, Perna F, Fontana S, Lechler RI, DePaoli AM, O'Rahilly S. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest. 2002; 110: 1093-1103.

Schutte AE, Schutte R. Leptin: a cardiovascular perspective. JEMDSA. 2012; 17: 72-76.

Silver DL, Jiang X, Tall AR. Increased high density lipoprotein (HDL), defective hepatic catabolism of ApoA-I and ApoA-II, and decreased ApoA-I mRNA in ob/ob Mice. J Biol Chem. 1999; 274: 4140-4146.

Aizawa-Abe M, Ogawa Y, Masuzaki H, Ebihara K, Satoh N, Iwai H, Matsuoka N, Hayashi T, Hosoda K, Inoue G, Yoshimasa Y, Nakao K. Pathophysiological role of leptin in obesity-related hypertension. J Clin Invest. 2000; 105: 1243-1252.

Cohen B, Novick D, Rubenstein M. Modulation of insulin activities by leptin. Science. 1997; 274: 1185- 1188.

De Courten M, Zimmet P, Hodge A, Collins V, Nicolson M, Staten M, Dowse G, Alberti KG. Hyperleptinemia: the missing link in metabolic syndrome. Diab Med. 1997; 14: 200-208.

Leyva F, Godsland IF, Ghatei M, Proudler AJ, Aldis S, Walton C, Bloom S, Stevenson JC.. Hyperleptinemia as a component of a metabolic syndrome of cardiovascular risk. Arterioscler Thromb Vasc Biol. 1998; 18: 928-933.

Adami GF, Civalleri D, Cella F, Marinari G, Camerini G, Papadia F, Scopinaro N. Relationships of serum leptin to clinical and anthropometric findings in obese patients. Obes Surg. 2002; 12: 623-627.

World Health Organization. Global Strategy on Diet, Physical Activity and Health. What is overweight and obesity? (at site http://www.who.int/dietphysicalactivity/childhood_what/en/)

Wallace TM, Levy JC, Matthews DR. Use and Abuse of HOMA Modeling. Diabetes Care. 2004; 27: 1487–1495.

Andreasson, A. N., Undén, AL., Elofsson, S., Brismar, K. Leptin and adiponectin: Distribution and associations with cardiovascular risk factors in men and women of the general population. Am J Hum Biol. 2012; 24: 595-601.

Liuzzi A, Savia G, Tagliaferri M, Lucantoni R, Berselli ME, Petroni ML, De Medici C, Viberti GC. Serum leptin concentration in moderate and severe obesity: relationship with clinical, anthropometric and metabolic factors. Int J Obes Relat Metab Disord. 1999; 23: 1066-1073.

Al-Shoumer KA, Al-Asousi AA, Doi SA, Vasanthy BA. Serum leptin and its relationship with metabolic variables in Arabs with type 2 diabetes mellitus. Ann Saudi Med. 2008; 28: 367-370.

García-Lorda P, Bulló M, Vilà R, del Mar Grasa M, Alemany M, Salas-Salvadó J. Leptin concentrations do not correlate with fat mass nor with metabolic risk factors in morbidly obese females. Diabetes Nutr Metab. 2001;14:329-36.

Brydon L, O'Donnell K, Wright CE, Wawrzyniak AJ, Wardle J, Steptoe A. Circulating leptin and stress-induced cardiovascular activity in humans. Obesity (Silver Spring). 2008; 16: 2642-2647.

Brydon L, Wright CE, O'Donnell K, Zachary I, Wardle J, Steptoe A. Stress-induced cytokine responses and central adiposity in young women. Int J Obes (Lond). 2008; 32: 443-450.

Alvarez-Aguilar C, Mondragón-Jiménez LI. Hyperleptinemia as a risk factor in obesity-related hypertension. Med Clin (Barc). 2004; 123: 766-769.

Benlian P, Cansier C, Hennache G, Khallouf O, Bayer P, Duron F, Carrat F, Couderc R, Chazouillères O, Bardet J, Bouchard P, Poupon R, Masliah J, Béréziat G. Comparison of new method for the direct and simultaneous assessment of LDL and HDL cholesterol with ultracentrifugation and established methods. Clin Chem. 2000; 46: 493–505.

Lonnqvist F, Wennlund A, Arner P. Relationship between circulating leptin and peripheral fat distribution in obese subjects. Int J Obes Relat Metab Disord. 1997; 21: 255-260.

Hodge AM, Boyko EJ, de Courten M, Zimmet PZ, Chitson P, Tuomilehto J, Alberti KG. Leptin and other components of the Metabolic syndrome in Mauritius- a factor analysis. Int J Obes Relat Metab Disord. 2001; 25: 126-131.

Ryan AS, Nicklas BJ. Age-related changes in fat deposition in mid-thigh muscle in women: relationships with metabolic cardiovascular disease risk factors. Int J Obes Relat Metab Disord. 1999; 23: 126-132.

Haluzík M, Fiedler J, Nedvídková J, Ceska R. Serum leptin levels in patients with hyperlipidemias. Nutrition. 2000; 16: 429-433.

Downloads

Published

2014-12-15

How to Cite

1.
Zerekidze T, Janjgava S, Asatiani K, Giorgadze E. Hyperleptinemia May Protect From Cardio-Vascular Complications: A Small Georgian Study. Open Access Maced J Med Sci [Internet]. 2014 Dec. 15 [cited 2021 Apr. 11];2(4):595-600. Available from: https://oamjms.eu/index.php/mjms/article/view/oamjms.2014.106

Issue

Section

B - Clinical Sciences